Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: The present invention relates to at least one novel anti-MCP-1 antibody having specific epitopes, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: The invention relates to a method of directing selection of biological therapeutic molecules to specific functional domains of the target biologic molecule. Selection is directed by the use of closely related molecules, where one is a decoy and the other contains the targeted domain or epitope. The invention is based on the use of physical data, which may be combined with derived data, to ascertain that the decoy and the target differ only in the specific functional domain or epitope where the binding will be directed.

Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: The object of this patent is an advance in the state of the art in the technique of manufacturing rods (2) aimed to be folded for the production of hangers (4) for the civil construction, the reinforced structures in particular, because it prevents the polygons generated in the folding of the hangers (4) form having non-co-planned edges as they are produced, which brings large savings to the process. The formation of hangers (4) with non-co-planned edges brings costs and delays to the civil construction, which are avoided with the use of the rod with octagonal core purpose-built for civil construction, object of this patent. Although the core of the rod with octagonal core purpose-built for civil construction is octagonal, according to the FIG. 8, its specific section is an octagonal structure, formed due to the corrugated material with which the rod (2) is made, according to FIG. 9.

Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

Abstract: A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact with the homolog target protein in a manner that would provide meaningful information about treatment efficacy or safety.

Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.